{"id":"egp-437-with-eyegate-ii-system","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular discomfort or irritation at iontophoresis site"},{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract progression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"EGP-437 is a dexamethasone analog formulated for transscleral iontophoretic delivery, which uses electrical current to enhance drug penetration through the sclera into the posterior segment of the eye. This targeted delivery approach aims to achieve therapeutic concentrations in the back of the eye while minimizing systemic exposure and anterior segment side effects associated with topical or systemic corticosteroids.","oneSentence":"EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:36:48.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Macular edema associated with retinal vein occlusion"},{"name":"Uveitis and other posterior segment inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT00694135","phase":"PHASE2","title":"Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis","status":"COMPLETED","sponsor":"Eyegate Pharmaceuticals, Inc.","startDate":"2008-06","conditions":"Uveitis, Anterior","enrollment":40},{"nctId":"NCT00765804","phase":"PHASE2","title":"Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye","status":"COMPLETED","sponsor":"Eyegate Pharmaceuticals, Inc.","startDate":"2008-10","conditions":"Dry Eye Syndrome","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexamethasone phosphate ophthalmic solution"],"phase":"phase_2","status":"active","brandName":"EGP-437 with EyeGate® II System","genericName":"EGP-437 with EyeGate® II System","companyName":"Eyegate Pharmaceuticals, Inc.","companyId":"eyegate-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation. Used for Macular edema associated with retinal vein occlusion, Uveitis and other posterior segment inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}